<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253731</url>
  </required_header>
  <id_info>
    <org_study_id>170151</org_study_id>
    <secondary_id>17-N-0151</secondary_id>
    <nct_id>NCT03253731</nct_id>
  </id_info>
  <brief_title>Interhemispheric Interaction of Parieto-Motor Cortico-Cortical Plasticity</brief_title>
  <official_title>Interhemispheric Interaction of Parieto-Motor Cortico-Cortical Plasticity in Human Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The two hemispheres of the brain are connected. Changes in one hemisphere affect the other&#xD;
      through this connection. Research has shown that training new skills in one hand improves the&#xD;
      same skills for the other hand. Researchers want to learn more about how the brain works to&#xD;
      transfer the skills to the other hand.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To learn how changes on one side of the brain affect the other side. To study the activity of&#xD;
      the left and right sides of the brain in healthy adults.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy volunteers ages 18-55 years old who are right-handed.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with a medical history and physical exam. They will complete a&#xD;
      questionnaire about their handedness. This may be done on paper or on a computer.&#xD;
      Participants may have urine pregnancy tests.&#xD;
&#xD;
      Participants will have 2 study visits.&#xD;
&#xD;
      Participants will have a structural magnetic resonance imaging (MRI) scan. MRI uses a strong&#xD;
      magnetic field and radio waves to take pictures of the brain. The scanner is a metal cylinder&#xD;
      in a strong magnetic field. Participants will lie on a table that slides in and out of the&#xD;
      cylinder.&#xD;
&#xD;
      Participants will have transcranial magnetic stimulation (TMS). Two wire coils will be placed&#xD;
      on the scalp. A brief electrical current passes through the coil and creates a magnetic pulse&#xD;
      that affects brain activity. Participants may be asked to tense certain muscles or do simple&#xD;
      tasks during TMS.&#xD;
&#xD;
      Participants will have electromyography. Small sticky pad electrodes will be attached to the&#xD;
      skin on the hands. Muscle activity will be recorded during the TMS procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      The purpose of this study is to evaluate the effect of long-term potentiation (LTP)-like&#xD;
      cortical plasticity induced by parieto-motor cortico-cortical paired associative stimulation&#xD;
      (cc-PAS) on the contralateral hemisphere and interhemispheric interactions in normal brain&#xD;
      using dual-site transcranial magnetic stimulation (TMS). We will explore the ipsilateral and&#xD;
      contralateral effects of cc-PAS over the left primary motor cortex (M1). We hypothesize that&#xD;
      the motor evoked potential (MEP) at S50 (the motor evoked potential) will change after cc-PAS&#xD;
      in the left hemisphere, which stimulates M1 after PPC (effective cc-PAS), not only on the&#xD;
      right first dorsal interosseous (FDI) muscle, but also the left FDI muscle.&#xD;
&#xD;
      In addition, we hypothesize that the MEP at S50 will change after cc-PAS in the left&#xD;
      hemisphere, which stimulates PPC after M1 (ineffective cc-PAS), on the right FDI muscle but&#xD;
      not the left FDI muscle.&#xD;
&#xD;
      Study population&#xD;
&#xD;
      We intend to study 15 healthy-volunteers to have 12 who complete the study. Subjects will&#xD;
      complete up to one screening visit and two study visits involving two intervention.&#xD;
&#xD;
      Design&#xD;
&#xD;
      Subjects will come for one screening visit and two outpatient study visits. The screening&#xD;
      visit and the first study visit can be performed the same day. The second study visit will be&#xD;
      done approximately 1 week after the first one. TMS-induced electromyographic (EMG) activity&#xD;
      of hand muscles will be recorded as MEPs. Using single TMS measure on both the left and right&#xD;
      M1, we will measure MEPs and input-out (I-O) curve for the right and left FDI muscle and&#xD;
      abductor digiti minimi (ADM) muscle, respectively. Using a paired-pulse TMS paradigm,&#xD;
      interhemispheric inhibition (IHI) from the left M1 to the right M1, short-interval&#xD;
      intracortical inhibition (SICI) and intracortical facilitation (ICF) will be measured on the&#xD;
      left FDI and ADM muscles. Then, the subjects will undergo two plasticity induction procedures&#xD;
      of the parieto-motor cc-PAS sessions. One of those is the hypothesized efficacious cc-PAS&#xD;
      session and the other one is the control, a hypothesized ineffective cc-PAS session. The two&#xD;
      sessions will be separated by approximately one week. Each session consists of 100 pairs of&#xD;
      double stimulation to the left PPC and left M1. MEPs, I-O curve on the bilateral M1, IHI from&#xD;
      the left M1 to the right M1, SICI and ICF will be remeasured during the 60 min after&#xD;
      receiving cc-PAS.&#xD;
&#xD;
      Outcome measures&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      The primary outcome measure will be MEP amplitude from the bilateral M1 with respect to time&#xD;
      (before, immediately and 30-45 min after intervention) after induction of cc-PAS plasticity&#xD;
      over the left hemisphere in each session. The amplitude of MEPs on each side of M1 will be&#xD;
      compared between before and after cc-PAS with respect to time, using ANOVA in each session.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      The degree of IHI from the left M1 to the right M1, SICI and ICF with respect to time&#xD;
      (before, immediately and 30-45 min after intervention) will be compared by the ANOVA test.&#xD;
      The degree of IHI and the change of IHI will be correlated with the primary outcome as&#xD;
      measured with a correlation analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left the NIH.&#xD;
  </why_stopped>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Actual">November 9, 2018</completion_date>
  <primary_completion_date type="Actual">November 9, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MEP amplitude at S50 over each side of M1 with respect to time (before, and immediately after and 30-45 min after cc-PAS over the left M1).</measure>
    <time_frame>3 timepoints</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>15 healthy volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Between the age of 18 and 55 years&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Illegal drugs use within the past 6 months based on history alone&#xD;
&#xD;
          -  Abnormal findings on neurologic examination&#xD;
&#xD;
          -  Have more than 7 alcoholic drinks a week in the case of a woman or 14 alcoholic drinks&#xD;
             a week in the case of a man&#xD;
&#xD;
          -  History of or current brain tumor, stroke, head trauma with loss of consciousness &gt;few&#xD;
             seconds, epilepsy or seizures&#xD;
&#xD;
          -  History of or current episode of major depression or any major psychiatric illness&#xD;
             (axis I disorders)&#xD;
&#xD;
          -  Current diagnosis of neurologic disorder&#xD;
&#xD;
          -  Presence of pacemaker, intracardiac lines, implanted pumps or stimulators, or metal&#xD;
             objects inside the eye or skull. Dental fillings and dental braces are allowed.&#xD;
&#xD;
          -  Open scalp wounds or scalp infection&#xD;
&#xD;
          -  Employees and/or staff of HMCS/NINDS&#xD;
&#xD;
          -  Taking benzodiazepines at the time of the entire study or within 12 days prior to the&#xD;
             study. NOTE: Medication will not be stopped or held for participation in this study.&#xD;
&#xD;
          -  Taking, at the time of the entire study or within 2 weeks prior to the study, any&#xD;
             medication that acts as a central nervous system stimulant or that is known to lower&#xD;
             seizure threshold, including, imipramine, amitriptyline, doxepin, nortriptyline,&#xD;
             maprotiline, chlorpromazine, foscarnet, ganciclovir, ritonavir, amphetamines,&#xD;
             ketamine, gamma-hydroxybutyrate (GHB), theophylline, mianserin, fluoxetine,&#xD;
             fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine,&#xD;
             bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine,&#xD;
             aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin,&#xD;
             ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporine,&#xD;
             chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium,&#xD;
             antihistamines, and sympathomimetics. NOTE: Medication will not be stopped or help for&#xD;
             participation in this study.&#xD;
&#xD;
          -  Being pregnant&#xD;
&#xD;
          -  You may not be eligible to have MRI or TMS in this study if:&#xD;
&#xD;
               -  You have metal in your body which would make having an MRI scan unsafe, such as&#xD;
                  pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial&#xD;
                  heart valves, cochlear implants or shrapnel fragments, or if you were a welder or&#xD;
                  metal worker, since you may have small metal fragments in the eye.&#xD;
&#xD;
               -  You are uncomfortable in small closed spaces (you have claustrophobia) so that&#xD;
                  you would feel uncomfortable in the MRI machine.&#xD;
&#xD;
               -  You are not able to lie comfortably on your back for up to 1 hour&#xD;
&#xD;
               -  You have a hearing loss reported in the history or detected in the routine&#xD;
                  physical examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Hallett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Awiszus F. TMS and threshold hunting. Suppl Clin Neurophysiol. 2003;56:13-23.</citation>
    <PMID>14677378</PMID>
  </reference>
  <reference>
    <citation>Bloom JS, Hynd GW. The role of the corpus callosum in interhemispheric transfer of information: excitation or inhibition? Neuropsychol Rev. 2005 Jun;15(2):59-71. Review.</citation>
    <PMID>16211466</PMID>
  </reference>
  <reference>
    <citation>Arai N, MÃ¼ller-Dahlhaus F, Murakami T, Bliem B, Lu MK, Ugawa Y, Ziemann U. State-dependent and timing-dependent bidirectional associative plasticity in the human SMA-M1 network. J Neurosci. 2011 Oct 26;31(43):15376-83. doi: 10.1523/JNEUROSCI.2271-11.2011.</citation>
    <PMID>22031883</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Plasticity</keyword>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

